2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two S&P/ASX All Ordinaries Index (ASX: XJO) ASX healthcare shares are making big moves today following the release of their quarterly performance updates.

One is racing ahead of the 0.2% losses posted by the All Ordinaries Index (ASX: XAO) in early afternoon trade on Thursday, while the other is decidedly lagging.

Which companies are we talking about?

Read on!

All Ords ASX healthcare share tumbles on cash burn

Turning to the laggard first, the Imugene Ltd (ASX: IMU) share price is down 8.5% at the time of writing, with shares trading for 4.3 cents apiece. That leaves the share price up 8% since this time last year. But shares have now tumbled a painful 61% in 2024.

The All Ords ASX healthcare share could be under added pressure today after reporting cash or equivalents of $54.3 million at the end of the September quarter. That's down from $93.1 million reported at the end of the June quarter.

The company said that net cash used in operating activities for the quarter amounted to $24 million, along with a milestone payment to Precision Biosciences for $14.4 million.

Highlights from the quarter included three complete responses in the company's azer-Cel Allogeneic CD19 CAR T Phase 1b trial in blood cancer (Diffuse Large B-Cell Lymphoma). The trial, conducted across 15 cancer centres in the United States and with plans to expand into Australia, aims to address patients who have relapsed after multiple prior treatments.

The quarter also saw the ASX healthcare share receive US Food and Drug Administration (FDA) Orphan Drug Designation for its VAXINIA product, which treats bile tract cancer.

And the first patient was dosed in a Phase 1 bile tract cancer expansion trial at St. Vincent's Hospital, Melbourne, with 10 patients set to be enrolled.

Which brings us to…

Paradigm share price lifts off on trial progress

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is up 2.5% at the time of writing, having earlier posted gains of 17.5%. Shares are currently changing hands for 20.5 cents apiece. That leaves the All Ords ASX healthcare share down 51% since this time last year.

Investors have been bidding up the Paradigm share price after the company reported on the "substantial progress" it made over the quarter in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis with its iPPS product.

Commenting on the recent achievements, Paradigm Biopharmaceuticals managing director Paul Rennie said, "The submission of our phase 3 protocol to the FDA is a significant milestone for Paradigm."

Rennie continued:

It represents the culmination of extensive work by our team and close collaboration with the FDA. We are confident that this progress, combined with the anticipated TGA [Therapeutic Goods Administration] response and our ongoing engagement with funding partners, positions us strongly as we move into this pivotal phase.

Our focus remains on delivering outcomes that will benefit patients and create long-term value for our shareholders.

As at 30 September, the ASX healthcare share had cash and equivalents of $13.14 million, down from $17.8 million at 30 June. Paradigm said it allocated "a significant portion" of its expenditure on research and development (R&D), focusing on advancing the Phase 3 clinical trial.

The company expects to receive $5 million to $6 million as part of its R&D incentive rebate.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »